; and (B) recommendations for measures (which may include legislative, regulatory, or other policy changes) to remove such impediments or otherwise promote such domestic production (which may include measures to ensure the economic viability of such domestic production or to address policies that competitively disadvantage such domestic production). (2) Coordination In preparing the report required by paragraph (1), the Secretary shall take into account any information provided to, and any findings and recommendations of, such Commission. (e) Definitions In this section: (1) The term designated critical medication means a critical medication for which a designation is in effect under subsection (b). (2) The term medication means a drug (as defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act), a biological product (as defined in section 351 of this Act), or a combination product (as described in section 503(g) of the Federal Food, Drug, and Cosmetic Act) that is approved, licensed, or cleared, as applicable, under chapter V of the Federal Food, Drug, and Cosmetic Act or section 351 of this Act. (3) The term public health emergency means a disease or disorder, including pandemics and other significant outbreaks of infectious diseases, bioterrorist attacks, the effects of chemical, biological, radiological, or nuclear agents or toxins, or the effects of extreme weather, earthquakes, or other natural disasters, that the Secretary has declared or may declare to be a public health emergency pursuant to section 319. (4) The term United States include the territories of the United States. . (b) Ensuring the availability of designated critical medications through the Strategic National Stockpile Section 319F–2 of the Public Health Service Act ( 42 U.S.C. 247d–6b ) is amended— (1) by amending subsection (a)(1) to read as follows: (1) In general (A) Maintaining stockpile or stockpiles The Secretary, in collaboration with the Assistant Secretary for Preparedness and Response, the Commissioner of Food and